Stevanato Group (NYSE:STVN) Hits New 1-Year Low – Time to Sell?

Stevanato Group S.p.A. (NYSE:STVN)’s stock price reached a new 52-week low during mid-day trading on Friday . The company traded as low as €16.30 ($17.91) and last traded at €16.30 ($17.91), with a volume of 810 shares traded. The stock had previously closed at €20.09 ($22.08).

Analysts Set New Price Targets

A number of brokerages have recently issued reports on STVN. Wolfe Research initiated coverage on shares of Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 target price on the stock. Bank of America raised their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, UBS Group lowered their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Stevanato Group presently has an average rating of “Moderate Buy” and a consensus price target of €25.70 ($28.24).

Stevanato Group Stock Performance

The stock has a market cap of $5.76 billion, a PE ratio of 38.63, a PEG ratio of 7.18 and a beta of 0.52. The stock has a fifty day simple moving average of €20.74 and a two-hundred day simple moving average of €20.61. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Equities analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

Several large investors have recently added to or reduced their stakes in the stock. First Bank & Trust raised its holdings in Stevanato Group by 7.3% during the fourth quarter. First Bank & Trust now owns 15,145 shares of the company’s stock worth $330,000 after purchasing an additional 1,036 shares in the last quarter. Truist Financial Corp raised its position in shares of Stevanato Group by 4.2% in the fourth quarter. Truist Financial Corp now owns 26,900 shares of the company’s stock valued at $586,000 after purchasing an additional 1,073 shares during the period. Oppenheimer Asset Management Inc. increased its position in Stevanato Group by 9.7% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,874 shares of the company’s stock worth $281,000 after buying an additional 1,141 shares during the period. US Bancorp DE grew its position in Stevanato Group by 17.9% during the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after buying an additional 1,295 shares in the last quarter. Finally, Captrust Financial Advisors raised its position in Stevanato Group by 12.7% in the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock worth $262,000 after purchasing an additional 1,480 shares in the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.